CS-807: SUSCEPTIBILITY AND CLINICAL EFFICACY

概要

論文の詳細を見る
Susceptibility to R-3763, the active free acid of a new oral cephem antibiotic CS-807, was tested in 137 clinical isolates of 6 species using the agar dilution method with an inoculum size of 106 cells/ml. The MIC range of R-3763 was biphasic for S. aureus, and peaked at 1.56μg/ml and at more than 50/μg/ml; it was 0.1-1.56μ/g/ml for E. coli, 0.1-0.78μg/ml for K. pneumoniae, less than 0.39μg/ml (79%) and 3.13-50μg/ml for M. morganii, 0.1μg/ml (93%)->100μg/ml for P. mirabilis and 0.39->100 μg/ml for S. marcescens. The antimicrobial activity of R-3763 against S. aureus was as good as that of four reference drugs, CEX, CCL, CFT and T-2525, and superior to CFIX. R-3763 against E. coli, K. pneumoniae, M. morganii, P. mirabilisand S. marcescens was superior to CEX, CCL and CFT and almost equal to CFIX and T-2525. Thirty patients with bacterial infections were treated with CS-807 at a daily oral dose of 200mg or 400mg for 3-14days. Clinical efficacy was excellent in 17, good in 12 and fair in 1. The total efficacy rate was 96.7%. Twenty-three pathogens-principally S. aureus, S. pneumoniae, E. coli and H. influenzae were isolated. All were eradicated after treatment with CS-807, except one strain of E. coli in a patient with chronic bronchitis. No adverse reactions or abnormal laboratory findings were observed.
公益社団法人日本化学療法学会の論文